Ikemefuna Nkanginieme, MD
Psychiatry · Canton, OHNPI 1972524049
Payments from drug & device makers
Across 173 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$681
- Teva Pharmaceuticals USA, Inc.$600
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$509
- Vanda Pharmaceuticals Inc.$324
- AbbVie$229
- Sunovion Pharmaceuticals Inc.$167
- plus $957 from 17 others
What the payments were for
- Food & beverage$3,36997%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 38 | $681 |
| Teva Pharmaceuticals USA, Inc. | 23 | $600 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $509 |
| Vanda Pharmaceuticals Inc. | 14 | $324 |
| AbbVie(2 entities) | 13 | $229 |
| Sunovion Pharmaceuticals Inc. | 11 | $167 |
| Otsuka America Pharmaceutical, Inc. | 4 | $153 |
| Avanir Pharmaceuticals, Inc. | 7 | $136 |
| Lundbeck LLC | 6 | $113 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| Johnson & Johnson | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Tempus AI, Inc | 3 | $63 |
| Noven Therapeutics, LLC | 3 | $58 |
| Almatica Pharma LLC | 3 | $53 |
| Corium, LLC | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Tris Pharma Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Indivior Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$108
How this compares
$3,468 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 27 | $104,318 |
| Abilify MaintenaAripiprazole | 28 | $76,769 |
| VraylarCariprazine Hcl | 43 | $62,260 |
| RexultiBrexpiprazole | 35 | $48,672 |
| TrintellixVortioxetine Hydrobromide | 44 | $22,914 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $17,866 |
| Lurasidone Hcl | 50 | $12,795 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,349 |
| FetzimaLevomilnacipran Hcl | 11 | $5,941 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 225 | $4,072 |
| QelbreeViloxazine Hcl | 12 | $3,998 |
| Lisdexamfetamine Dimesylate | 14 | $3,515 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 38 | $2,821 |
| Quetiapine Fumarate | 170 | $2,767 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 45 | $2,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $153 | $125,44163 claims |
| Johnson & JohnsonInvega Sustenna | $81 | $104,31827 claims |
| AbbVieVraylar, Fetzima | $229 | $68,20154 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $69 | $30,26363 claims |
| Alkermes, Inc.Lybalvi | $681 | $17,86612 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $24 | $3,99812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Canton
- Shishuka MalhotraCanton$15M
- Pradeep ManudhaneCanton$1.5M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.